Peptides Similar to CJC-1295 DAC
Compare CJC-1295 DAC with related peptides and alternatives
📌TL;DR
- •3 similar peptides identified
- •CJC-1295 without DAC: Same modified GRF(1-29) peptide sequence; both stimulate GH via GHRH receptor
- •Sermorelin: Both are GHRH receptor agonists that stimulate pituitary GH release
Quick Comparison
| Peptide | Similarity | Key Differences |
|---|---|---|
| CJC-1295 DAC (current) | - | - |
| CJC-1295 without DAC | Same modified GRF(1-29) peptide sequence; both stimulate GH via GHRH receptor | CJC-1295 without DAC lacks albumin binding capability; half-life ~30 min vs 6-8 days; requires 2-3 daily injections vs weekly |
| Sermorelin | Both are GHRH receptor agonists that stimulate pituitary GH release | Sermorelin is the natural GRF(1-29) without modifications; shorter half-life; previously FDA-approved for pediatric GH deficiency diagnosis |
| Ipamorelin | Both stimulate GH release from the pituitary | Ipamorelin is a ghrelin-mimetic (GHRP) acting at the GHS-R1a receptor; CJC-1295 DAC acts at the GHRH receptor; complementary mechanisms |
CJC-1295 without DACSame modified GRF(1-29) peptide sequence; both stimulate GH via GHRH receptor
Differences
CJC-1295 without DAC lacks albumin binding capability; half-life ~30 min vs 6-8 days; requires 2-3 daily injections vs weekly
Advantages
Shorter half-life allows more discrete GH pulses and faster clearance if adverse effects occur
Disadvantages
Requires much more frequent dosing; less convenient; less sustained IGF-1 elevation
SermorelinBoth are GHRH receptor agonists that stimulate pituitary GH release
Differences
Sermorelin is the natural GRF(1-29) without modifications; shorter half-life; previously FDA-approved for pediatric GH deficiency diagnosis
Advantages
FDA-approved history (though discontinued); longer clinical use experience
Disadvantages
Very short half-life requiring daily injection; susceptible to DPP-IV degradation; less potent GH stimulation
IpamorelinBoth stimulate GH release from the pituitary
Differences
Ipamorelin is a ghrelin-mimetic (GHRP) acting at the GHS-R1a receptor; CJC-1295 DAC acts at the GHRH receptor; complementary mechanisms
Advantages
Ipamorelin produces more selective GH release without significant cortisol or prolactin elevation
Disadvantages
Short half-life requiring multiple daily injections; no sustained IGF-1 elevation
Peptides Related to CJC-1295 DAC#
CJC-1295 DAC belongs to the class of growth hormone secretagogues, compounds that stimulate the release of endogenous growth hormone from the anterior pituitary. This class includes GHRH analogs (which act at the GHRH receptor) and ghrelin-mimetic peptides (which act at the growth hormone secretagogue receptor, GHS-R1a). Understanding the differences between these compounds is important for researchers evaluating their relative merits.
CJC-1295 without DAC (Modified GRF 1-29)#
The most direct comparison is between CJC-1295 DAC and its non-DAC counterpart, often referred to as CJC-1295 without DAC, modified GRF(1-29), or Mod GRF 1-29. Both compounds share the identical modified peptide sequence with the same four amino acid substitutions for DPP-IV resistance. The sole difference is the presence or absence of the Drug Affinity Complex moiety.
Without the DAC, the peptide cannot bind albumin and has a plasma half-life of approximately 30 minutes. This fundamentally changes the pharmacokinetic and pharmacodynamic profile. CJC-1295 without DAC produces acute, discrete GH pulses that resolve within 1 to 2 hours, requiring administration 2 to 3 times daily to maintain stimulation. CJC-1295 DAC, by contrast, maintains sustained GHRH receptor activation throughout the weekly dosing interval.
The practical differences are significant. The non-DAC version offers more physiologically pulsatile GH stimulation and faster clearance if adverse effects occur, making it potentially safer from a risk management perspective. However, the multiple daily injection requirement is a major practical disadvantage for compliance.
Sermorelin#
Sermorelin (also known as GRF 1-29 or Geref) is the unmodified 29-amino acid fragment of human GHRH. It was previously FDA-approved as a diagnostic agent for GH deficiency (Geref Diagnostic) and for treatment of pediatric GH deficiency, though both products have been discontinued from the US market.
Sermorelin lacks the amino acid substitutions present in CJC-1295, making it susceptible to rapid DPP-IV degradation with a plasma half-life of less than 10 minutes. This necessitates daily subcutaneous injection, typically before bedtime to coincide with the natural nocturnal GH surge.
Compared to CJC-1295 DAC, sermorelin produces less potent and shorter-duration GH stimulation. However, its prior FDA approval provides a level of clinical validation that CJC-1295 DAC does not have. Sermorelin also has a longer history of clinical use in the anti-aging and hormone optimization communities, providing more anecdotal experience regarding its effects and side effect profile.
Ipamorelin#
Ipamorelin is a synthetic pentapeptide that acts as a selective agonist at the growth hormone secretagogue receptor (GHS-R1a), the endogenous receptor for ghrelin. Unlike CJC-1295 DAC, which works through the GHRH pathway, ipamorelin stimulates GH release through the ghrelin/GHSR pathway.
The two pathways are complementary: GHRH primarily drives GH synthesis and release, while ghrelin-mimetics primarily potentiate the GH-releasing effect of GHRH and directly depolarize somatotroph cells. This complementary mechanism underlies the widely discussed practice of combining GHRH analogs with ghrelin-mimetics for synergistic GH stimulation.
Ipamorelin is notable for its selectivity among the ghrelin-mimetic class. Unlike GHRP-6 and GHRP-2, ipamorelin does not significantly increase cortisol or prolactin levels at GH-stimulating doses. However, it has a short half-life requiring multiple daily injections, making it less convenient than the weekly CJC-1295 DAC dosing.
Tesamorelin#
Tesamorelin (Egrifta) is a GHRH analog that is FDA-approved for the treatment of HIV-associated lipodystrophy. It consists of the full 44-amino acid sequence of human GHRH with a trans-3-hexenoic acid modification at the N-terminus to improve stability.
Tesamorelin is the only GHRH analog with an active FDA approval, making it the clinical reference standard for this class. Clinical trials demonstrated significant reduction in visceral adipose tissue in HIV patients, along with increased IGF-1 levels. However, tesamorelin requires daily subcutaneous injection due to its relatively short half-life, making CJC-1295 DAC more convenient from a dosing perspective.
Summary Comparison#
| Feature | CJC-1295 DAC | CJC-1295 no DAC | Sermorelin | Ipamorelin | Tesamorelin |
|---|---|---|---|---|---|
| Receptor target | GHRH-R | GHRH-R | GHRH-R | GHS-R1a | GHRH-R |
| Half-life | 6-8 days | ~30 min | <10 min | ~2 hours | ~30 min |
| Dosing frequency | Weekly | 2-3x daily | Daily | 2-3x daily | Daily |
| FDA status | Investigational | Not approved | Discontinued | Not approved | Approved (HIV lipodystrophy) |
| Clinical data | Phase 1-2 | Limited | Phase 3 (historic) | Phase 2 | Phase 3 |
| GH pulse pattern | Sustained elevation + pulses | Discrete pulses | Discrete pulses | Discrete pulses | Discrete pulses |
Clinical Positioning#
CJC-1295 DAC occupies a unique position among GH secretagogues due to its prolonged duration of action. The once-weekly dosing schedule is unmatched by any other compound in this class, offering a significant practical advantage for sustained GH axis stimulation. However, the long half-life also means that adverse effects cannot be rapidly reversed, which is a safety disadvantage compared to shorter-acting alternatives.
For researchers, the choice between CJC-1295 DAC and its alternatives depends on the specific research question: sustained GH/IGF-1 elevation favors CJC-1295 DAC, while studies requiring discrete pulsatile GH stimulation favor the non-DAC version or ipamorelin. For clinical applications, tesamorelin remains the only FDA-approved option in the GHRH analog class.
Related Reading#
Frequently Asked Questions About CJC-1295 DAC
Explore Further
Disclaimer: For educational purposes only. Not medical advice. Read full disclaimer